本文首发于公众号"私募排排网"。 迈德瑞投资简介 迈德瑞投资是一家总部于法国巴黎，专注于趋势跟踪CTA超过12年的量化对冲基金。法国母公司Metori Capital创办 于2016年，由原法国兴业银行旗下领先资产管理全球首席投资官Nicolas博士带领核心投研团队创办。Metori创始团 队拥有深厚的金融、数学专业背景，投资经验均超过20年，Nicolas博士任职领先资产管理全球首席投资官期间，曾 管理全球超1000亿欧元资产。 目 公司简介 投资模式 办公城市 C G 量化趋势跟踪CTA。 漫国、中国 & 管理规模 50.21亿人民币会 (全球总规模:约50.21亿人民币,截止到2025/3/31%境外美元按照7.3汇率换算) C 公司股权 迈德瑞中国趋势策略最早于2012年进入中国市场 ，是迈德瑞创始人Nicolas博士与Guillaume博士，基于中国期货市 场独立研发的趋势跟踪量化CTA策略，策略在2014年6月就开始与国内公募合作专户运行。 迈德瑞中国设立于2019 年，于2020年获批私募牌照，是境内第28家外资，第1家法资私募基金管理人 。迈德瑞中国实缴资本金400万美 元，也是实缴资本最大的 ...

金十数据5月15日讯，当地时间5月14日，美国对冲基金公司Point72创始人史蒂文·科恩（Steven Cohen） 表示，他认为美国经济很有可能因关税威胁放缓。科恩在纽约举行的一场投资会议上表示："我们认为 美联储不会马上采取行动，因为美联储仍会担心关税带来的通胀问题。"科恩预计美国明年国内生产总 值（GDP）将增长1.5%。 美对冲基金公司创始人：美经济很可能因关税威胁而放缓 ...

虽然我们尚未陷入衰退，但经济增速显著放缓。 亿万富翁、对冲基金Point72 Asset Management创始人Steve Cohen：美国爆发经济衰退的概率现在为45% 左右。 ...

Core Viewpoint - Alexander Mashinsky, former CEO of Celsius Network, was sentenced to 12 years in prison after pleading guilty to fraud, marking a significant downfall for a leader once celebrated in the crypto industry [1][5]. Group 1: Legal Proceedings and Sentencing - Mashinsky was sentenced by U.S. District Judge John G. Koeltl after pleading guilty to commodities fraud and manipulating the Celsius token [2]. - His legal troubles began in 2023 with his arrest on multiple fraud charges, coinciding with Celsius's $4.7 billion settlement with the Federal Trade Commission [3]. - The guilty plea and sentencing conclude a lengthy case involving charges from the Securities and Exchange Commission and the Commodity Futures Trading Commission [5]. Group 2: Fraud Allegations - Prosecutors accused Mashinsky of misleading investors regarding the safety and profitability of Celsius's yield-generating platform while secretly liquidating tens of millions of dollars in personal assets [4]. - The fraud scheme orchestrated by Mashinsky and Celsius is described as multi-billion dollar, reflecting a broader trend of legal actions against prominent figures in the crypto sector [5]. Group 3: Industry Context - Mashinsky's downfall parallels that of other crypto executives like Sam Bankman-Fried, highlighting a pattern of significant legal repercussions within the cryptocurrency industry [5]. - The collapse of Celsius and other firms like Three Arrows Capital and Voyager Digital can be traced back to the broader impact of failed projects, such as Do Kwon's stablecoin, which wiped out approximately $40 billion from the market [16][19].

Eisler Capital已裁员约15%，以期在资产减少和交易亏损的情况下降低成本。据一位知情人士透露，这 项决定影响了这家总部位于英国伦敦的投资公司约45名员工，主要从事技术、中台和后台工作，因为该 公司正在利用技术来填补人员空缺。此次裁员还包括约五名投资专业人士，他们管理着Eisler 35亿美元 资产中的约3%。 ...

市场消息：对冲基金Eisler在重组中裁员15%以削减成本。 ...

Billionaire hedge fund manager Bill Ackman has been attempting to use real estate developer Howard Hughes Holdings (HHH 2.82%) to create a "modern-day Berkshire Hathaway" for some time. Now, it looks like a deal has finally been reached that could allow him to get started.I've previously discussed Ackman's two prior proposals (links in text), but here are the short versions:In January, Ackman proposed taking a majority stake in Howard Hughes by purchasing shares for $85. Depending on how many shareholders t ...

Core Insights - Renaissance Technologies is recognized as one of the world's most successful hedge funds, primarily due to its Medallion Fund, which achieved an annualized return of 39% after fees from 1988 to 2021 [1] - The firm has notable long equity holdings, including significant positions in Novo Nordisk, United Therapeutics, and Palantir Technologies, reflecting its investment strategies and market outlook [2][14] Group 1: Novo Nordisk - At the end of 2024, Renaissance's third-largest long equity holding was Novo Nordisk, with a stake valued at $715 million, indicating strong conviction in the company [3][5] - Novo Nordisk's stock generated a total return of approximately 480% from the end of 2017 to its peak in June 2024, but has since declined by 56% as of April 29 [4] - Renaissance reduced its holdings in Novo by around 9% from Q2 2024 to Q4 2024, while the stock is currently trading at levels similar to the end of 2022 [5] Group 2: United Therapeutics - Renaissance maintained a significant position in United Therapeutics, valued at around $737 million at the end of 2024, with a total return of approximately 285% since Q2 2019 [7][8] - The company has six FDA-approved medications, with its leading product, Tyvaso, generating over $1.6 billion in sales in 2024, reflecting a 31% growth from 2023 [9] - The continued large position in United Therapeutics suggests confidence in the company's ability to grow sales and develop new treatments for rare conditions [9] Group 3: Palantir Technologies - As of Q4 2024, Palantir Technologies became Renaissance's largest holding, with a position valued at over $1.7 billion, having increased by over 1,700% since the end of 2022 [11] - Renaissance reduced its stake in Palantir by over 40% from Q3 2024, which may have been a strategic move given the stock's significant rise of over 200% since that time [12] - Analysts have expressed concerns about Palantir's high forward price-to-earnings multiple, indicating potential downside risks [13]

知情人士透露，Point72 Asset Management宏观投资组合经理Yau Ng在这家 资产规模近370亿美元的对冲 基金巨头任职六年多后已经退休。另外，一位知情人士表示，驻迪拜的投资组合经理Alex Blanchard也 已离开该公司。 ...

Billionaire Ray Dalio is one of the most respected investors out there. Bridgewater Associates, the hedge fund he founded, is generally considered to be the largest hedge fund in the world, with assets under management topping out at $168 billion in 2022. The 75-year-old is known for his "all-weather" portfolio, including gold, balancing risks across asset classes to build a portfolio that can perform well in virtually any economic scenario. He pays close attention to the macro environment, and after a care ...